Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
IPO Year: 2014
Exchange: NASDAQ
Website: protaratx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2023 | $22.00 | Buy | Guggenheim |
| 11/8/2021 | $32.00 → $34.00 | Outperform | Oppenheimer |
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-surge-over-400-says-oppenheimer/
HC Wainwright & Co. analyst Andrew Fein reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.95) by 2.11 percent. This is a 21.25 percent decrease over losses of $(0.80) per share from the same period last year.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Susquehanna raised the price target for Occidental Petroleum Corporation (NYSE:OXY) from $70 to $81. Susquehanna analyst Biju Perincheril maintained a Positive rating. Occidental Petroleum shares rose 0.9% to close at $66.63 on Friday. See how other analysts view this stock. Keybanc boosted the price target for Alphabet Inc. (NASDAQ:GOOGL) from $165 to $175. Keybanc analyst Justin Patterson maintained an Overweight rating. Alphabet shares fell 1.2% to close at $154.09 on Friday. See how other analys
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $26 to $30.
HC Wainwright & Co. analyst Andrew Fein maintains Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.
Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TARA-002 program, the company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations. Data were derived from three-month evaluable NMIBC patients with CIS pooled across the company’s ADVANCED-1 Phase 1a, Phase 1b-expansion and ADVANCED-2 Phase 2 trials. The overall three-month complete response (CR) rate before reinduction for 16 evaluable patients treated across the three trials with varying BCG status was 38%
Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 25.93% to $8.06. The company's market cap stands at $236.5 million. Etao International Co (NASDAQ:ETAO) shares moved upwards by 25.61% to $3.58. The market value of their outstanding shares is at $18.3 million. Indaptus Therapeutics (NASDAQ:INDP) shares rose 11.11% to $2.5. The company's market cap stands at $21.3 million. scPharmaceuticals (NASDAQ:SCPH) stock moved upwards by 10.7% to $5.69. The company's market cap stands at $205.1 million. Molecular
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate of 9,143,380 shares of its common stock (Shares) or, for certain purchasers, pre-funded warrants to purchase an aggregate of 1,700,000 shares of its common stock (Pre-Funded Warrants), in each case, along with warrants to purchase an aggregate of 10,843,380 shares of its common stock (Common Warrants), in a private placement financing with certain institutional accredited investors. Each Share, along with its attached Common Warrant, has a purchase pr
10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
S-8 - Protara Therapeutics, Inc. (0001359931) (Filer)
10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
EFFECT - Protara Therapeutics, Inc. (0001359931) (Filer)
424B3 - Protara Therapeutics, Inc. (0001359931) (Filer)
S-3 - Protara Therapeutics, Inc. (0001359931) (Filer)
10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in mid-2025In pediatric LMs patients, TARA-002 demonstrated encouraging results and was generally well-tolerated in the first cohort of Phase 2 STARBORN-1 trial; initial results from next cohort expected in 1H 2025Received Fast Track designation from the U.S. FDA for IV Choline Chloride; expect to dose first patient in THRIVE-3 registrational trial in 1Q 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative the
Remain on track to initiate registrational THRIVE-3 trial in 1Q' 2025 NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Intravenous (IV) Choline Chloride, the Company's investigational IV phospholipid substrate replacement therapy, as a source of choline for adult and adolescent patients on parenteral support (PS) for whom oral or enteral nutrition is not possible, insufficient, or contraindicated. In the U.S. alone, there are approximately 4
TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H'25 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced completion of the first cohort of the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of pediatric patients with lymphatic malformations (LMs). Enrollment is now underway in additional cohorts. "The initial data is compelling and reflective of the significa
78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injuryIV Choline Chloride could fill a significant unmet medical need for this populationCompany expects to dose first patient in pivotal PK trial for IV Choline Chloride in Q1 2025 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the results of THRIVE-1, a prospective, observational study evaluating the prevalence of choline deficiency and liver in
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on Monday, September 9, 2024 at 1:30 pm ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advan
On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024 Expect to dose first patient in pivotal trial for IV Choline Chloride in Q1 2025 Current cash resources are approximately $90 million, including net proceeds from April 2024 private placement, expected to fund operations into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2024. "The first half of the year has been m
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an aggregate of 118,400 shares of common stock to Lisa Schlesinger, Protara's newly appointed Vice President, Head of New Product Development and Market Access. Each stock option has an exercise price per share equal to $2.23 per share, Protara's closing trading price on June 24, 2024, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:00 pm ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committe
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024Reached alignment with FDA on registrational path forward for IV Choline Chloride in patients dependent on parenteral nutritionCurrent cash resources, together with approximately $45.0 million in gross proceeds from April 2024 private placement, expected to fund operations into 2026 NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cance
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate of 9,143,380 shares of its common stock (Shares) or, for certain purchasers, pre-funded warrants to purchase an aggregate of 1,700,000 shares of its common stock (Pre-Funded Warrants), in each case, along with warrants to purchase an aggregate of 10,843,380 shares of its common stock (Common Warrants), in a private placement financing with certain institutional accredited investors. Each Share, along with
Guggenheim resumed coverage of Protara Therapeutics with a rating of Buy and set a new price target of $22.00
Oppenheimer reiterated coverage of Protara Therapeutics with a rating of Outperform and set a new price target of $34.00 from $32.00 previously
HC Wainwright & Co. initiated coverage of Protara Therapeutics with a rating of Buy and set a new price target of $40.00
Oppenheimer initiated coverage of Protara Therapeutics with a rating of Outperform and set a new price target of $43.00
- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Operations into Mid-2024 - NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. "Following a productive 2021, we are well poised to advance our pipeline in 2022, in particular, we are excited to have commenced our Phase 1 study of TARA-002 in non-muscle invasive b
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer. "We are thr
- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing and Expected to be Completed by Year-End - - Company Plans to Engage with FDA to Determine Clinical Trial Design for TARA-002 in Lymphatic Malformations - - Strong Cash, Cash Equivalents, and Investments Position of $145M as of June 30, 2021 - NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the se
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Jane Huang, M.D. to its Board of Directors. Dr. Huang, an experienced biotech executive and proven leader throughout the development lifecycle of multiple oncology therapeutics globally, currently serves as Chief Medical Officer, Hematology at BeiGene, Ltd. “It is a great privilege to welcome Dr. Huang to our Board of Directors,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “As a proven industry leader wi
- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End - - On Track to Complete TARA-002 GMP Scale up and Comparability in 2H, 2021 - - Plan to Engage with FDA and Initiate Clinical Study of TARA-002 in Lymphatic Malformations - - Strong Cash, Cash Equivalents and Investments Position of $155M as of March 31, 2021 - NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. "
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer, effective immediately. Dr. Olivo brings to Protara more than 15 years of experience in oncology translational and clinical research and global drug development, most recently serving as Vice President, Breast Cancer Clinical Development Lead at Gilead Sciences, Inc. (formerly Immunomedics, Inc.). "We are very excited to welcome Dr. Olivo to our leadership team," said Jesse Sheffer
- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End - - In Discussions with FDA on Next Steps Needed to File BLA for TARA-002 in Lymphatic Malformations - - On Track to Complete GMP Scale up and Comparability in 2H, 2021 - - Strong Cash Position of $169M as of December 31, 2020 - NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a busines
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. Ms. Smith brings to Protara over 20 years of diverse leadership experience within the healthcare industry, most recently serving as Chief Commercial Officer at ZS Pharma. “It is with great excitement that we welcome Cynthia to our Board of Directors,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “As an accomplished leader with a proven track record in key commercial a